CHINA NATIONAL MEDICINES CORP (600511) Q3 2025 earnings summary

Executive summary

• Revenue for the first nine months reached ¥39.38 billion, up 3.56% year-over-year, with Q3 revenue at ¥13.75 billion, a 3.58% increase compared to the same quarter last year.

• Net profit attributable to shareholders for the first nine months was ¥1.49 billion, up 0.74% year-over-year; Q3 net profit was ¥543.72 million, up 13.10% year-over-year.

• Basic and diluted EPS for the first nine months were ¥1.9778, up 0.74% year-over-year; Q3 EPS was ¥0.7206, up 13.10% year-over-year.

Financial highlights

• Gross margin improved as operating costs grew slower than revenue; operating profit for the first nine months was ¥1.95 billion.

• Total assets at Q3-end were ¥35.13 billion, up 0.56% from year-end; equity attributable to shareholders was ¥18.04 billion, up 5.34%.

• Net cash flow from operating activities for the first nine months was -¥2.05 billion, a further decline from -¥1.03 billion in the prior year period.

• Non-recurring gains for the first nine months totaled ¥22.12 million, mainly from entrusted investment income and government subsidies.

Key financial ratios and metrics

• Weighted average ROE for the first nine months was 8.50%, down 0.67 percentage points year-over-year.

• Q3 weighted average ROE was 3.06%, up 0.12 percentage points year-over-year.